Similar companies
Income Statement (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Revenue | 3.2M | 32.8% |
| Gross Profit | 380,000 | 135.4% |
| Cost of Revenue | 2.9M | 18.3% |
| Operating expense | 12M | 6.8% |
| Net Income | -8.7M | 14.9% |
| EBITDA | -8.7M | 15.3% |
Balance Sheet (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Total Assets | 45M | 5.9% |
| Total Liabilities | 19M | 6.1% |
| Total Equity | 25M | 17.3% |
| Shares Outstanding | 60M | 23.8% |
Cash Flow (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Cash from operations | -7.5M | 24.7% |
| Cash from investing | 98,000 | 1080% |
| Cash from financing | 9.8M | 1082.1% |
EPS
Financial Highlights for Cue Biopharma in Q3 '24
Cue Biopharma reported a revenue of 3.2M, which is a 32.8% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 380,000, marking a 135.4% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 2.9M, a -18.3% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 12M, showing a -6.8% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -8.7M, showing a 14.9% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -8.7M, showing a 15.3% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for Cue Biopharma with growth in revenue, gross profit, and net income.
